What retinal diseases are most interesting to Allergan? C. David Nicholson, PhD, chief R&D officer, discusses Allergan’s Phase III trials of Abicipar, a promising treatment for AMD that could reduce the number of injections. He also looks earlier in the pipeline, sharing details of a gene therapy drug for retinitis pigmentosa as well as the company’s CRISPR collaboration with Editas Medicine.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.